Swedish boost for Glaxo drug

Monday 07 September 1998 23:02 BST

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

SHARES IN Glaxo Wellcome, the world's second-biggest drug maker, rose 26p to 1,840p after it said it had won approval for Seretide, its treatment for asthma, in Sweden.

Sweden is the first country to approve the drug and will act as the reference state in the procedure to obtain approval in the European Union. Seretide is the first drug to allow asthma suffers to achieve 24-hour control of the condition with a twice-daily dose from a single inhaler, Glaxo said.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Stay up to date with notifications from The Independent

Thank you for registering

Swedish boost for Glaxo drug

Join our commenting forum

Thank you for registering